ANO5 Gene Limb‑Girdle Muscular Dystrophy Type 2L (LGMD2L) Genetic Test in UAE

Executive Summary & Core Metrics

Executive Clinical Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑15189‑Aligned NGS processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (8 AM – 11 PM).
Clinical Guidance: Complimentary Tele‑Health Post‑Test Interpretation by a DHA‑Licensed Consultant Medical Geneticist.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

This molecular assay provides definitive diagnosis for autosomal recessive limb‑girdle muscular dystrophy type 2L (LGMD2L) by sequencing the entire ANO5 coding region. The test identifies pathogenic variants with 99.9% analytical sensitivity, guiding prognosis, family planning, and eligibility for emerging therapies.

Test Overview & Methodology

The ANO5 Gene NGS Test delivers a comprehensive molecular diagnosis for LGMD2L by analysing the full coding region and flanking splice sites using next‑generation sequencing with copy number variant (CNV) detection. This DHA‑recognised assay offers superior diagnostic yield compared to traditional single‑gene Sanger sequencing.

Feature	Our ANO5 NGS Test	Standard Single‑Gene (Sanger)
Methodology	Full‑Gene Next‑Generation Sequencing (NGS) with CNV analysis	Sanger sequencing of selected exons
Turnaround Time	3–4 Weeks	8–12 Weeks
Diagnostic Yield	>99% for LGMD2L variants	70–85% (misses deep intronic/CNV)
Pre‑test Genetic Counselling	Complimentary DHA‑guided session	Often not included

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) advises: “An ANO5 genetic result provides a definitive molecular diagnosis and opens the door to tailored management strategies. I strongly recommend post‑test genetic counselling to correlate the identified variants with the patient’s clinical phenotype, enabling accurate prognosis, informed family planning, and access to emerging therapies. This test is a tool for empowerment, not a label.”

Medication Safety Advisory

⚠️ Important Precaution

Do not discontinue any prescribed medications (including corticosteroids, immunosuppressants, or physiotherapy regimens) before consulting your treating neurologist. A genetic diagnosis does not override existing acute management protocols. Always seek professional medical advice before making changes to your treatment plan.

Exclusion Criteria & Emergency Red Flags

Exclusion: Individuals with active systemic infection requiring hospitalisation; inability to provide informed consent (legal guardian required for minors per Federal Decree‑Law No. 4 of 2016 on Medical Liability).
Exclusion: No confirmed clinical indication for LGMD2L (e.g., isolated myalgia without proximal muscle weakness).
Red Flag: Seek immediate emergency care if you experience sudden‑onset respiratory distress, severe dysphagia, or rapid loss of ambulation within days.
Red Flag: New‑onset cardiac symptoms (palpitations, syncope, chest tightness) require urgent cardiology evaluation independent of genetic results.

Patient FAQ & Clinical Guidance

1. What is the clinical utility of the ANO5 NGS test for LGMD2L?

This test identifies disease‑causing variants in the ANO5 gene with 99.9% sensitivity, enabling definitive diagnosis, carrier testing, and prenatal or preimplantation genetic options. The NGS panel covers all coding exons and flanking splice sites, often eliminating the need for muscle biopsy. Results directly inform physiotherapy intensity, orthotic prescriptions, and eligibility for clinical trials targeting dysferlin‑related pathways.

2. How is the sample collected and transported under UAE regulations?

Our DHA‑licensed phlebotomists perform a 2 mL whole‑blood draw using ISO‑certified cold‑chain kits, ensuring sample integrity from 8 AM to 11 PM. DNA extraction occurs at a CAP‑accredited laboratory. All processes comply with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Home collection vehicles are monitored via real‑time temperature logs.

3. Will my health insurance cover the 2800 AED cost?

Most UAE insurers cover genetic testing for neuromuscular disorders when pre‑authorised with ICD‑10 code G71.0 and a DHA‑registered neurologist or geneticist referral. Our billing team handles direct verification via WhatsApp (+971 54 548 8731) before sample collection. For self‑pay patients, a detailed receipt with LOINC 85047‑9 is issued for potential reimbursement. Flexible payment plans are available through DHA‑approved partners.

UAE Regulatory & Data Privacy Adherence

Accreditation & Compliance: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) • MOHAP Licensed Facility 9834453 • Fully compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your genetic data is encrypted, access‑controlled, and processed exclusively within UAE jurisdiction.

📞 24/7 Genetic Helpline: +971 54 548 8731

Clinical & Logistical Metadata

Test Name	ANO5 Gene Limb‑Girdle Muscular Dystrophy Type 2L (LGMD2L) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Whole Blood (2 mL) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM)
Methodology Used	Next‑Generation Sequencing (NGS) with CNV Analysis
ICD-10-CM Code	G71.0
LOINC Code	85047-9
DHA Facility License & Address	License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE